Hengrui three-quarter report out of the Meirui, Dong A gum, ha medicine and other nearly 100 pharmaceutical companies disclosed the notice

On October 19, Hengrui Pharmaceuticals announced that its operating income for the first three quarters of 2020 was RMB19,413 million, up 14.57% YoY, and its net profit was RMB4,259 million, up 14.02% YoY.
In addition, according to Sina Pharmaceutical incomplete statistics, the pharmaceutical manufacturing industry has nearly 100 enterprises disclosed the first three quarters of the earnings forecast, of which more than 40 enterprises pre-growth, more than 30 enterprises pre-decrease, there is some uncertainty.
pre-growth enterprises in the pre-growth enterprises, according to Sina Pharmaceutical incomplete statistics, there are Huada gene, Changchun high-rise, Rip biology, Science and Technology biology and other more than 40 enterprises.
the highest growth rate of sanxiang creatures, which had just landed on august 28 this year.
Sanxiang Bio expects net profit to be 1.97 billion yuan to 2.07 billion yuan in the first three quarters of 2020, up 10,472.64 percent from a year earlier to 11,009.32 percent.
Shengxiang Bio said the growth was mainly due to the company's third quarter, due to the second wave of outbreaks in some overseas countries, the global outbreak is still in a state of instability.
and the third quarter began to enter the flu-like autumn and winter festival, many countries around the world to increase preparations for autumn and winter, to prevent the new crown and influenza common epidemic, to avoid cross-infection input, thereby driving the company's new crown nucleic acid detection reagents, nucleic acid detection equipment, related supplies and other products demand for a substantial increase.
the outbreak-related product sales have had a positive impact on the performance, Murray Medical reported a net profit of 4,956 million to 5.323 billion yuan in the first three quarters, making it the largest company with the highest net profit.
in addition to the outbreak caused the company's related anti-epidemic products such as monitors, ventilators, infusion pumps, new crown antibody reagents, portable color super, mobile DR demand increased, the company's benign internal reform, travel expenses and other operating expenses to effectively control also become a profitable growth point.
addition, Jiu'an Medical is one of the few companies to turn a profit.
the outbreak, Jiuan Medical Company achieved a reversal of its performance losses by exporting anti-epidemic products such as thermometers to overseas exports, and expected net profit attributable to shareholders of listed companies to be between 320 million and 380 million yuan in January-September 2020.
the overseas epidemic has not yet eased, consumer demand for thermometers, oxygen meters and other products still exists, overseas consumer demand will still drive corporate profits.
Pre-reduced enterprises and pre-reduced enterprises, according to Sina Pharmaceutical incomplete statistics, Northeast Pharmaceuticals, Yan'an Bikang, Hainan Hai Pharmaceuticals, Special One Pharmaceuticals, Jinling Pharmaceuticals, Guangji Pharmaceuticals, Lidman, Berry Gene and other more than 30 enterprises pre-reduced Of these, 10 of them will make their first losses, namely: Tonghua Jinma, Ha Pharmaceuticals, Jinshi Asia Pharmaceuticals, Asia Pacific Pharmaceuticals, Undelievered Pharmaceuticals, Yanyuan Pharmaceuticals, ST Hua Plastics, Yihua Health, Cylon Pharmaceuticals and DongA Gum.
Yihua Health was affected by the epidemic and the national macroeconomic environment, coupled with the termination of some of the company's hospital custody services business and other reasons, decreased year-on-year: 6641.23% to 8949.90%, the largest loss.
first loss in the third quarter due to the loss of overseas investment in GNC and frequent personnel changes.
east A gum in addition to the outbreak shock, due to the sales mode reform appeared the first loss.
Asia Pacific Pharmaceutical Co., Ltd. also lost money in the third quarter due to increased financial expenses, shifting production base, loss of control of Shanghai New Peak Biopharmaceutical Co., Ltd. and its subsidiaries as a result of the company's public offering of convertible bonds to raise interest.
Among the five companies that continued to lose money, Junshi Bio, Shenzhou Cells, Consino, Zexi Pharmaceuticals, four companies listed on the board, due to continuous product research and development investment, coupled with the fact that Junshi Bio just listed a drug other enterprises are not listed, this quarter will continue to lose money.
st eye drug by the parent company's pharmaceutical center discontinued relocation and transformation and pneumonia outbreak, etc. , will continue to lose money.